Medical Management of Obesity as it Affects Reflux

James D. Haddad; Shawn L. Shah

doi:10.1177/26345161211069183

Medical Management of Obesity as it Affects Reflux

James D. Haddad, Shawn L. Shah

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.

Original language	English (US)
Pages (from-to)	328-335
Number of pages	8
Journal	Foregut
Volume	1
Issue number	4
DOIs	https://doi.org/10.1177/26345161211069183
State	Published - Dec 2021

Keywords

GERD
obesity
pharmacotherapy

ASJC Scopus subject areas

Gastroenterology
Surgery
Oncology

Access to Document

10.1177/26345161211069183

Cite this

@article{f498a759d9384f3898d781cea65cfbfe,

title = "Medical Management of Obesity as it Affects Reflux",

abstract = "Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.",

keywords = "GERD, obesity, pharmacotherapy",

author = "Haddad, {James D.} and Shah, {Shawn L.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2021",

month = dec,

doi = "10.1177/26345161211069183",

language = "English (US)",

volume = "1",

pages = "328--335",

journal = "Foregut",

issn = "2634-5161",

publisher = "SAGE Publications Inc.",

number = "4",

}

TY - JOUR

T1 - Medical Management of Obesity as it Affects Reflux

AU - Haddad, James D.

AU - Shah, Shawn L.

N1 - Publisher Copyright: © The Author(s) 2022.

PY - 2021/12

Y1 - 2021/12

N2 - Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.

AB - Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.

KW - GERD

KW - obesity

KW - pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85163340978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163340978&partnerID=8YFLogxK

U2 - 10.1177/26345161211069183

DO - 10.1177/26345161211069183

M3 - Review article

AN - SCOPUS:85163340978

SN - 2634-5161

VL - 1

SP - 328

EP - 335

JO - Foregut

JF - Foregut

IS - 4

ER -

Medical Management of Obesity as it Affects Reflux

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this